Devens, MA, USA — Veranova, a global leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced today that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration (FDA) New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification. This result demonstrates Veranova’s commitment to driving the highest standards of…
In an era when precision is paramount, the latest research published in Nature Reviews Drug Discovery has reignited conversations around the need for ultra-high-quality antibody libraries in drug development."The study underscores the pivotal role of precise molecular targeting—especially antibodies—in decoding the complexities of protein functions and advancing therapeutic strategies for intractable diseases." A scientist from Creative Biolabs says, which is a biotechnology solution provider playing a key role nowadays offering high-performance antibody discovery platforms to accelerate the…
Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (Nasdaq: INSM),…
Dr Simon Hirst, CEO and Founder of Sygnature Discovery has been awarded a prestigious honorary degree of Doctor of Science (D.Sc.) by The University of Nottingham.
The honorary degree recognises Simon’s outstanding contribution to science and the pharmaceutical industry. Simon’s oration was delivered by Professor Emeritus Chris Moody, who recommended Simon should receive the Doctor of Science honoris causa. The Vice-Chancellor Professor Jane Norman presented the award on behalf of the University. The presentation took place as part of the University’s summer graduation…
Amsbio reports how the Sasaki Lab within the School of Veterinary Medicine at the University of Pennsylvania (USA) devised a protocol in which induced pluripotent stem cells (iPSCs) could be utilized to produce reconstituted human testes.
Since the original 2020 publication of their groundbreaking research, Dr Kotaro Sasaki’s team has made significant progress in reconstituting human testis-like tissue from iPSCs.
A 2025 blog update describes a new protocol for generating xenogeneic reconstituted testes (xrTestes) that support human spermatogonial…
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant (branded as Lynkuet™) for the treatment of moderate to severe hot flushes and night sweats associated with menopause. These symptoms, also known as vasomotor symptoms, affect a significant proportion of women and can have a considerable impact on quality of life.• Elinzanetant is the first non-hormonal dual NK-1,3 antagonist treatment for menopause symptoms to receive regulatory approval anywhere in the world. It works by targeting neurokinin-1 and neurokinin-3 receptors, introducing a new class of…
Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies. The report also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than those elsewhere.
Whilst the number of deals in 2024 decreased slightly compared to previous years, the average deal size increased, with life science companies raising £3.54bn across 595 deals in 2024 - up from the £2.91bn raised via 656 deals in 2023. Crucially, average deal size…
The Value of Collective SupportWelcome to the August 2025 edition of the One Nucleus eNews. The continuing cash-flow challenges in the life science sector in terms of raising investment, M&A deals, grant funding, or client recruitment by the service sector are making life tough at both the company and employee levels for many.
In such times, I find it reassuring to see how the ‘all in this together’ collective spirit comes to the fore and new strategies emerge to combat the downturn.
It definitely felt like a community coming together at the recent ON Helix conference, with…
Cambridge, UK – 4 August 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
This international trial has recruited 29 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial results are expected by the end of 2025.
The COMPOSER-1 study is designed to investigate the safety, tolerability, and initial signals of…
UK-based creative leader joins global organisation for life science sales and marketing professionalsSAMPS — the US-based global professional network for sales and marketing professionals in science — has announced the appointment of David Lister, CEO of UK-based life science creative agency CLOK, to its Board of Directors.David’s appointment reflects SAMPS’s commitment to expanding its global reach and fostering innovation in how science is communicated and commercialised. Based in the UK, David brings over 20 years of experience helping life science companies clarify complex ideas and…